Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases

Abstract Data on the efficacy of computer tomography guided brachytherapy (CT-BRT) for limited liver metastases is lacking; to assess CT-BRT’s role in inducedoligoprogression in colorectal cancer (CRC), we performed a retrospective cohort study on CRC patients with metastatic disease, treated with 2...

Full description

Saved in:
Bibliographic Details
Main Authors: Paweł Cisek, Łukasz Kuncman, Barbara Alicja Jereczek-Fossa, Ewa Wojtyna, Magdalena Orzechowska, Sylwia Sroka, Izabela Kordzińska-Cisek, Jacek Fijuth, Mateusz Bilski
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-09227-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849334579962314752
author Paweł Cisek
Łukasz Kuncman
Barbara Alicja Jereczek-Fossa
Ewa Wojtyna
Magdalena Orzechowska
Sylwia Sroka
Izabela Kordzińska-Cisek
Jacek Fijuth
Mateusz Bilski
author_facet Paweł Cisek
Łukasz Kuncman
Barbara Alicja Jereczek-Fossa
Ewa Wojtyna
Magdalena Orzechowska
Sylwia Sroka
Izabela Kordzińska-Cisek
Jacek Fijuth
Mateusz Bilski
author_sort Paweł Cisek
collection DOAJ
description Abstract Data on the efficacy of computer tomography guided brachytherapy (CT-BRT) for limited liver metastases is lacking; to assess CT-BRT’s role in inducedoligoprogression in colorectal cancer (CRC), we performed a retrospective cohort study on CRC patients with metastatic disease, treated with 2–5 lines of systemic therapy, who achieved induced oligoprogression with up to four liver metastases eligible for CTBRT. In 75 patients, median overall survival (mOS) was 17 months, and median progression-free survival (mPFS) was 10 months during a 16-month follow-up. The mOS was not dose-dependent. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were found in 8, 31, 47, and 15%, respectively. The mOS in patients with CR, PR, SD, and PD was 23, 17, 14, and 11 months, respectively. Disease Control Rate (DCR) with a high dose influenced OS, while PFS was impacted by extrahepatic metastases (especially in abdominal/pelvic lymph nodes), the number of metastases, and DCR with a high dose. Treatment toxicity was very low (Grade 3—1%, > Grade 3–0%). We report the largest cohort demonstrating CT-BRT as an effective local treatment for colorectal liver metastases in induced oligoprogression, with minimal toxicity.
format Article
id doaj-art-c443b36dce0f4d14913f5e38b43ecb49
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-c443b36dce0f4d14913f5e38b43ecb492025-08-20T03:45:32ZengNature PortfolioScientific Reports2045-23222025-07-0115111110.1038/s41598-025-09227-0Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastasesPaweł Cisek0Łukasz Kuncman1Barbara Alicja Jereczek-Fossa2Ewa Wojtyna3Magdalena Orzechowska4Sylwia Sroka5Izabela Kordzińska-Cisek6Jacek Fijuth7Mateusz Bilski8Department of Brachytherapy, Saint John’s Cancer CenterDepartment of Radiotherapy, Medical University of LodzDepartment of Radiation Oncology, European Institute of Oncology IRCCSDepartment of Medical Physics, Saint John’s Cancer CenterDepartment of Molecular Carcinogenesis, Medical University of LodzDepartment of Medical Physics, Saint John’s Cancer CenterDepartment of Oncology, Saint John’s Cancer CenterDepartment of Radiotherapy, Medical University of LodzDepartment of Brachytherapy, Saint John’s Cancer CenterAbstract Data on the efficacy of computer tomography guided brachytherapy (CT-BRT) for limited liver metastases is lacking; to assess CT-BRT’s role in inducedoligoprogression in colorectal cancer (CRC), we performed a retrospective cohort study on CRC patients with metastatic disease, treated with 2–5 lines of systemic therapy, who achieved induced oligoprogression with up to four liver metastases eligible for CTBRT. In 75 patients, median overall survival (mOS) was 17 months, and median progression-free survival (mPFS) was 10 months during a 16-month follow-up. The mOS was not dose-dependent. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) were found in 8, 31, 47, and 15%, respectively. The mOS in patients with CR, PR, SD, and PD was 23, 17, 14, and 11 months, respectively. Disease Control Rate (DCR) with a high dose influenced OS, while PFS was impacted by extrahepatic metastases (especially in abdominal/pelvic lymph nodes), the number of metastases, and DCR with a high dose. Treatment toxicity was very low (Grade 3—1%, > Grade 3–0%). We report the largest cohort demonstrating CT-BRT as an effective local treatment for colorectal liver metastases in induced oligoprogression, with minimal toxicity.https://doi.org/10.1038/s41598-025-09227-0BrachytherapyLiver metastasesOligoprogressionMetastasis-directed therapy
spellingShingle Paweł Cisek
Łukasz Kuncman
Barbara Alicja Jereczek-Fossa
Ewa Wojtyna
Magdalena Orzechowska
Sylwia Sroka
Izabela Kordzińska-Cisek
Jacek Fijuth
Mateusz Bilski
Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases
Scientific Reports
Brachytherapy
Liver metastases
Oligoprogression
Metastasis-directed therapy
title Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases
title_full Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases
title_fullStr Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases
title_full_unstemmed Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases
title_short Computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases
title_sort computed tomography guided high dose rate brachytherapy for induced oligoprogression of colorectal cancer liver metastases
topic Brachytherapy
Liver metastases
Oligoprogression
Metastasis-directed therapy
url https://doi.org/10.1038/s41598-025-09227-0
work_keys_str_mv AT pawełcisek computedtomographyguidedhighdoseratebrachytherapyforinducedoligoprogressionofcolorectalcancerlivermetastases
AT łukaszkuncman computedtomographyguidedhighdoseratebrachytherapyforinducedoligoprogressionofcolorectalcancerlivermetastases
AT barbaraalicjajereczekfossa computedtomographyguidedhighdoseratebrachytherapyforinducedoligoprogressionofcolorectalcancerlivermetastases
AT ewawojtyna computedtomographyguidedhighdoseratebrachytherapyforinducedoligoprogressionofcolorectalcancerlivermetastases
AT magdalenaorzechowska computedtomographyguidedhighdoseratebrachytherapyforinducedoligoprogressionofcolorectalcancerlivermetastases
AT sylwiasroka computedtomographyguidedhighdoseratebrachytherapyforinducedoligoprogressionofcolorectalcancerlivermetastases
AT izabelakordzinskacisek computedtomographyguidedhighdoseratebrachytherapyforinducedoligoprogressionofcolorectalcancerlivermetastases
AT jacekfijuth computedtomographyguidedhighdoseratebrachytherapyforinducedoligoprogressionofcolorectalcancerlivermetastases
AT mateuszbilski computedtomographyguidedhighdoseratebrachytherapyforinducedoligoprogressionofcolorectalcancerlivermetastases